Key Takeaways
- Women’s health is the fastest-growing functional segment in North American generic probiotics, at a projected 6.6% CAGR from 2026 to 2031 (MarketsandMarkets, July 2026).
- Symptoms outrank life stages. Only 16% of women name hormonal health as a concern, so fatigue, stress, mood, sleep and focus make stronger lead messages (FMCG Gurus).
- Kaneka Probiotics built its SupplySide Global 2026 booth around women’s health, with samples that showed formulation versatility across bars, lip balm and freeze-dried melts.
- 8 postbiotics across five wellness areas, including the new KABP® Mindbiome Ease and KABP® Mindbiome Bright, give brands strain level precision in up to ten formats.
- KABP® Gyntima Menopause is the first and only commercially available probiotic ingredient to clinically demonstrate both estrogen modulation and menopausal symptom improvement.
Why Is Women’s Health Growing So Fast in Probiotics?
Women’s health has the highest projected growth of any functional segment in North American generic probiotics, at a 6.6% CAGR from 2026 to 2031, growing from $513.0M to $705.0M, according to MarketsandMarkets (July 2026). Digestive health is still the largest segment at $1.33B in 2025, which makes women’s health the faster-moving opportunity rather than the biggest one today.
The wider probiotic category is also outpacing the supplement market around it, which gives brands a stronger base to build on.
| Market signal | Figure |
| Women’s health growth in North American generic probiotics | 6.6% CAGR, the highest of any functional segment |
| Digestive segment size in generic probiotics, 2025 | $1.33B, the largest segment |
| Global probiotic supplements | About $10.3B, with a +4.5% five-year CAGR |
| Dietary supplements overall | +2.4% five-year CAGR |
Retail is moving in the same direction. The NBJ 2026 Supplement Business Report names women’s health, including menopause, hormonal and urinary tract support, as a meaningful growth driver for a major supplement manufacturer in the category.
Over one-third of women globally use vitamin and mineral supplements to address symptoms of their hormonal cycles or menopause (Innova Market Insights, 2025), and probiotics are riding that wave: women’s health is the second-fastest-growing segment in North American general probiotics, at an 8.8% CAGR from 2026 to 2031 (MarketsandMarkets, July 2026).
How Should Brands Market Women’s Health Probiotics?
Brands should lead with symptoms and use life stage as context. FMCG Gurus consumer data shows that hormonal health ranks last among women’s health concerns, with only 16% of women naming it.
| Health concern | Women concerned |
| Bone and joint | 37% |
| Digestive | 32% |
| Skin | 27% |
| Mental wellbeing | 25% |
| Weight | 25% |
| Hormonal health | 16% |
Women respond more to fatigue, stress, mood, sleep and focus than to labels like “hormonal” or “menopause.” FMCG Gurus also reports that female-specific positioning has struggled when it relies on pink packaging or menstrual labeling.
Mental wellbeing and cognition are a clear opening. About 35% of Millennial women and 40% of Gen X women are concerned about mental wellbeing, and roughly 40% are concerned about cognitive health. Among Millennial women, 65% find cognitive health products appealing.
For brand teams
A women’s product does not have to be a hormone product. It needs to solve the symptom the shopper actually feels, then make clear who it is for. Precision matters more than a longer strain list: strains selected for a specific function, at a clinically studied dose, give brands a clearer story than a high CFU count.
Brain fog, stress, and poor sleep aren’t limited to menopause. For brands looking to support cognition across a wider audience, our new postbiotics offer two options: KABP® Mindbiome Ease for adult sleep, stress, and mood, and KABP® Mindbiome Bright for cognitive performance in children ages 8 to 12. Both debuted at SupplySide Global 2026 and are covered in the portfolio section below.

What Did Kaneka Probiotics Show at SupplySide Global 2026?
Kaneka Probiotics built its entire SupplySide Global 2026 booth around women’s health. We exhibited at Booth #4165 at Mandalay Bay Convention Center in Las Vegas during the Expo Hall dates of October 28 to 30, following the October 1 launch of our women’s health campaign, Connected Thinking. Precision Probiotics.
The campaign is built on one idea: women’s health is interconnected, and it starts in the gut. Its jigsaw identity represents that connected picture, and its messaging leads with what she wants, a product made for her, before revealing the science behind it. Fifteen years of women-centered research back the portfolio, working through pathways such as the estrobolome to connect gut health with hormone, brain and immune outcomes.

Our women’s health portfolio now carries the Gyntima® name used across the rest of the world, and the booth showed how far it reaches. Nutraceuticals World previewed our focus on the connections between gut health and women’s whole-body physiology. In a Nutritional Outlook interview recorded at the show, Jordi Riera, Chief Business Officer and Probiotics Division lead, described women’s health as the area where we have put the most R&D effort in recent years. He pointed to an estrobolome-modulating probiotic for perimenopausal women, KABP® Gyntima Balance for vaginal health, and expansion into broader women’s wellness.
Jordi also joined the panel “Gut Health Revolution: The Biotic Boom” on Tuesday, October 27, alongside Amy Smith, Ph.D., George Paraskevakos and Bob Durkin, with Hank Schultz as moderator. The session covered the standards of evidence a health claim needs, the trade-offs in each formulation choice, and how R&D, regulatory and clinical teams can align early to launch products that are both credible and effective. Jordi’s main takeaway for formulators: a clinically tested, designated strain beats a trending genus or a bigger CFU count, in any format.

At the booth
- Samples that show formulation versatility: protein bars made with SOUND Foods and Solnul®, freeze-dried probiotic candy melts in coffee and mango flavors made with melt & jet Technology, and a biotic lip balm made with the postbiotic KABP® Sakei. The bars and melts use KABP® Intensive G.I., a clinically studied, three-strain probiotic that survives stomach acid to reach the gut and supports a healthy GI tract.
- Samples of KABP® Gyntima Menopause and KABP® Sakei: two of the ingredients behind our recent industry recognition. Finished products across skin and menopause support also included Floradapt® Estrobolome Support capsules.
- Launch of KABP® Mindbiome Ease and KABP® Mindbiome Bright: the first time these two new postbiotics were shown. The main researcher for KABP® Mindbiome Bright was present to discuss the newly published trial.



Recognition around the show
- KABP® Gyntima Menopause won First Place in the Biotics category of the Nutrition Industry Executive 2026 New Ingredient Awards.
- KABP® Gyntima Menopause was selected to present at the CRN Innovation Exchange on October 6, 2026.
- KABP® Sakei was Runner-Up in the Nutricosmetics category of the WholeFoods Magazine Ingredient Choice Award.
Independent analysts noticed the shift too. In its SupplySide Global 2026 takeaways, Kline + Company described women’s health as the clearest example of biotics moving beyond digestive positioning, and noted that Kaneka Probiotics built its presence around gut health and women’s whole-body physiology.
With 9 studies in the pipeline, we are continuing to build the science behind women’s health. Read the full press release: [PRESS RELEASE LINK TO BE ADDED]. You can also visit our SupplySide Global 2026 event page.

What Is in the Gyntima® Women’s Health Portfolio?
The KABP® Gyntima portfolio is organized by the biological axis each solution supports, which gives brand teams a clear way to match an ingredient to a product concept.
| Solution | Strains | Axis |
| KABP® Gyntima Menopause | L. plantarum KABP®-051, L. brevis KABP®-052 and P. acidilactici KABP®-021 | Gut estrobolome modulation |
| KABP® Gyntima Balance | L. gasseri KABP®-064 | Vaginal microbiome modulation |
| KABP® Gyntima Restore | L. plantarum KABP®-061, live and heat-treated option | Vaginal microbiome modulation |
| KABP® Gyntima Cyscare | L. plantarum KABP®-062 and KABP®-063 | Urogenital microbiome support |
| KABP® Sakei | L. sakei KABP®-065 | Gut-skin axis support |
KABP® Gyntima Menopause gives supplement formulators a differentiated, science-backed foundation to meet rising demand for natural, hormone-free menopause support.

What the published research shows
KABP® Gyntima Menopause is the first and only commercially available probiotic ingredient to clinically demonstrate both estrogen modulation and menopausal symptom improvement. Three solutions in the portfolio have published research behind them:
| Solution | What the research showed | Source |
| KABP® Gyntima Menopause | A randomized controlled trial published in August 2026 showed improvement in menopause-related symptoms and quality of life. Earlier research showed it helped sustain estrogen levels in peri- and postmenopausal women by modulating the estrobolome. | Rodríguez-Palmero et al., Menopause, 2026; Honda et al., Journal of Medicinal Food, 2024 |
| KABP® Gyntima Balance | A Kaneka Probiotics led trial showed for the first time that a L. gasseri strain can colonize the vaginal tract after oral administration. KABP®-064 was detected in 55.9% of participants after 18 days, with fewer non-lactobacilli genera and a shift toward lactobacilli-dominated community state types. | Perez et al., Microbiology Spectrum, 2025 |
| KABP® Sakei | A placebo-controlled trial showed heat-treated L. sakei KABP®-065 supports skin elasticity and firmness in healthy middle-aged women, with particular benefits for women older than 40. | Sawashita et al., Journal of Cosmetic Dermatology, 2025 |
Doses stay practical for formulators. Menopause, Balance and Cyscare are each dosed at 1 billion CFU per dose, and Sakei at 10 billion cells per dose.
What Is in Kaneka’s Postbiotic Portfolio?
Kaneka Probiotics offers 8 postbiotics across five wellness areas, two of them built for women’s health.
Postbiotic
A preparation of inactivated microorganisms, and in some cases their components, that supports health without needing live cells. The benefit does not depend on viability, which changes how an ingredient behaves in a formula.
| Wellness area | Postbiotic | Strain or source | Focus |
| Women’s health | KABP® Gyntima Restore | L. plantarum KABP®-061 | Vaginal microbiome support, in suppository format |
| Women’s health | KABP® Sakei | L. sakei KABP®-065 | Healthy-looking skin appearance |
| Cognitive health and sleep | KABP® Mindbiome Ease (new) | L. plantarum SNK12 | Sleep, stress and mood support |
| Cognitive health | KABP® Mindbiome Bright (new) | B. longum KABP®-042 and L. plantarum KABP®-051 | Cognitive performance support |
| Cardiometabolic health and weight | LipiGO® | Saccharomyces cerevisiae (BGCC extract) | Weight management support |
| Cardiometabolic health and weight | Akkermansia AKK ProBio® | A. muciniphila | Metabolic health and healthy ageing |
| Immune health | KABP® BreviBiotic | L. brevis subsp. coagulans KP-08 | Innate immune support |
| Oral health | KABP® Dentisani | S. dentisani KABP®-054 | Oral pH and microbiome balance |
New at SupplySide Global 2026
KABP® Mindbiome Ease is a heat-killed Lactiplantibacillus plantarum SNK12, derived from sunki, a traditional Japanese fermented pickle. It is positioned for sleep, occasional stress and mood support, and its format list includes functional foods alongside capsules, gummies, shots, sticks and liquids.
KABP® Mindbiome Bright pairs heat-killed B. longum KABP®-042 and L. plantarum KABP®-051 for cognitive performance support. It was studied in school-aged children, which opens a path into family and children’s health products.
Both raw materials store at room temperature and carry a three-year shelf life when unopened. Their sell sheets made their first appearance at our SupplySide Global booth.
KABP® Mindbiome Ease is validated by two clinical trials, and KABP® Mindbiome Bright by one human clinical trial, with additional studies underway. Clinical doses are 100 billion cells per day for Ease, and 10 billion cells per day for Bright, split evenly between KABP®-042 and KABP®-051.
Why Do Postbiotics Matter for Format Innovation?
According to FMCG Gurus, 48% of probiotic buyers prefer food and drink, while 36% prefer supplements. NBJ reports that gummies hold 24.6% of supplement sales, or $18.26B, but growth has cooled to 7.9%. Powders grew 16.2% and liquids 9.7%. NBJ sources describe live probiotics in gummies as the ultimate goal, with dosage and stability as the barrier.
Because postbiotic benefits do not depend on viability, Kaneka postbiotics offer predictable potency, room temperature stability and no cold chain requirement. That gives brand teams broad format compatibility and fewer supply chain constraints. Our postbiotics are available in ten formats:
- Capsules
- Tablets and chewable tablets
- Raw material powder
- Shots
- Sticks
- Liquids, flavored and unflavored
- Blister packs
- Cap-in-cap
- Sachets
- Gummies
Across the women’s health portfolio, formats also include creams and vaginal tablets, so brands can build beyond oral products.
Our ingredients also travel well beyond the capsule. At the SupplySide booth, protein bars, freeze-dried candy melts and a lip balm gave brand teams something to hold, which is often the fastest way to see how an ingredient could fit their own product line.
Our take
Format is where women’s health products will separate. Brands that can bring a symptom-led story to bars, melts, drinks or topicals will reach shoppers that a capsule alone cannot. Download our postbiotic solutions guide →
What to Look For When Building a Women’s Health Product
Five criteria separate a product with a clear point of view from category noise.

1. A named symptom, not just a life stage
Start with the feeling the shopper wants to change, such as poor sleep, stress, low focus or fatigue. Life stage works best as context that tells her the product is for her.
2. Strain level precision
A longer strain list is not a stronger story. Look for individual strains selected for a specific function, with a clear mechanism and a studied dose.
3. Format fit for your channel
Match the format to where the product will be sold and how it will be used. Bars, melts, drinks, topicals and gummies all reach shoppers that capsules miss.
4. Stability you can plan around
Room temperature storage, a long raw material shelf life and no cold chain keep supply chains simpler. Ask for the finished format stability data, not only the raw material specifications.
5. A supplier that supports your claims work
Supplier sell sheets are written for B2B education, and brands are responsible for their own legal and regulatory review before using any claim in consumer materials. Work with a team that can talk through which claims fit your product and market.
Precision Formulation for Women’s Health
Women’s health rewards brands that are specific: a specific symptom, a specific strain and a specific format. Kaneka Probiotics offers probiotic and postbiotic building blocks for each, from menopause and vaginal health to sleep, stress and focus.

If you are planning a women’s health launch, our formulation science team can help match an ingredient to your symptom story and your format.
Why brands build with Kaneka Probiotics
- Clinically studied strains
- Women’s health expertise
- Proprietary microbiome solutions
- Flexible delivery formats
- Commercialization support
- A 500+ strain library
Connected Thinking. Precision Probiotics.
Frequently Asked Questions About Women’s Health Probiotics and Postbiotics
Why is women’s health a growth opportunity for probiotic brands?
MarketsandMarkets projects women’s health to have the highest CAGR of any functional segment in North American generic probiotics, at 6.6%. Digestive health is the largest segment today, but women’s health is growing fastest.
How should brands market women’s health probiotics?
Lead with the symptom, such as sleep, stress, mood or focus, and use life stage as context. FMCG Gurus data shows only 16% of women name hormonal health as a concern, while many more respond to everyday symptoms.
What did Kaneka Probiotics showcase at SupplySide Global 2026?
Our Booth #4165 was built entirely around women’s health. It featured samples of KABP® Gyntima Menopause and KABP® Sakei, bars, lip balm and melts that show formulation versatility, and the first sell sheets for KABP® Mindbiome Ease and KABP® Mindbiome Bright.
What is a postbiotic?
A postbiotic is a preparation of inactivated microorganisms, and in some cases their components, that supports health without needing live cells. Its benefit does not depend on viability.
How many postbiotics does Kaneka Probiotics offer?
Kaneka Probiotics offers 8 postbiotics across women’s health, cognitive health and sleep, cardiometabolic health and weight, immune health and oral health. Two are designed for women’s health: KABP® Gyntima Restore and KABP® Sakei.
Which formats are available for Kaneka postbiotics?
Our postbiotics are available as capsules, tablets and chewable tablets, raw material powder, shots, sticks, liquids, blister packs, cap-in-cap, sachets, gummies and some functional foods.
Are KABP® Mindbiome Ease and KABP® Mindbiome Bright new?
Yes. Both debuted at SupplySide Global 2026, where their sell sheets were shown for the first time. Ease supports sleep, stress and mood, and Bright supports cognitive performance. Ease is validated by two clinical trials and Bright by one, with additional studies underway.
What published research supports the Gyntima® portfolio?
Published research covers menopause symptoms and quality of life, estrogen levels in peri- and postmenopausal women, oral colonization of the vaginal tract and skin elasticity and firmness. The research table in the Gyntima® portfolio section above lists the findings and citations. You can find much of our clinical research here https://kanekaprobiotics.com/clinical-evidence/
Sources
1. MarketsandMarkets. North America Precision Biotics, General Probiotics, and Generic Probiotics Market. July 2026.
2. Innova Market Insights. Global Ingredients for Women’s Health Supplements. May 2025.
3. Euromonitor, via Probiota. February 2026.
4. FMCG Gurus. Women’s health and probiotic consumer data.
5. NBJ. 2026 Supplement Business Report.
6. Nutraceuticals World. SupplySide Global 2026 preview.
7. Nutritional Outlook. Supporting Women’s Health Through Probiotic Innovation.
8. Kline + Company. SupplySide Global 2026 takeaways.
9. Kaneka Probiotics press release. October 1, 2026. [PRESS RELEASE LINK TO BE ADDED]
10. Rodríguez-Palmero et al. Menopause. 2026.
11. Honda et al. Journal of Medicinal Food. 2024.
12. Perez et al. Microbiology Spectrum. 2025.
13. Sawashita et al. Journal of Cosmetic Dermatology. 2025.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

